Gyre Therapeutics EV/EBIT GYRE

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2012.

Today, Oct 23, 2026: n/m; an operating loss
Last meaningful: 61.9×; May 2026
4-year median: 52.6×
4-year range: 0.1× to 98.5×
Peer median: 6.3×

Gyre Therapeutics has no meaningful EV/EBIT today: it made an operating loss of $16.7M over the last twelve months.

It was last meaningful in May 2026, at 61.9×.

On the days it had one over the last 4 years, its median was 52.6×, from 0.1× in May 2023 to 98.5× in Oct 2025.

EV/EBIT over time

median 52.6×

The dashed line is the 4-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	61.9×	55.1×	68.2×
2025	59.5×	40.7×	98.5×
2024	2.1×	1.3×	2.8×
2023	3.1×	0.1×	6.0×
2022	n/m a value too high to mean anything
2021	n/m a value too high to mean anything
2020	n/m a value too high to mean anything
2019	n/m a value too high to mean anything
2018	n/m a value too high to mean anything
2017	n/m a value too high to mean anything
2016	n/m a value too high to mean anything
2015	n/m a value too high to mean anything
2014	n/m a value too high to mean anything
2013	30.2×	12.7×	62.7×
2012	26.7×	9.2×	60.4×

Against its peers

Companies in Drug Manufacturers - General nearest Gyre Therapeutics' size, closest first, today.

Company	EV/EBIT
GYREGyre Therapeutics	n/m
CRMDCorMedix	2.3×
ZVRAZevra Therapeutics	2.9×
IRWDIronwood Pharmaceuticals	3.5×
COLLCollegium Pharmaceutical	9.4×
PBYIPuma Biotechnology	15.6×
ABUSArbutus Biopharma	4.9×
ARVNArvinas	n/m
AMPHAmphastar Pharmaceuticals	12.2×
OMEROmeros	n/m
PCRXPacira BioSciences	7.6×
Peer median	6.3×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Gyre Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.